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Introduction
Acute stroke is the leading cause of disability in the
modern society1. In developed countries, stroke is the
second cause of death1, and in Croatia it is the leading
cause of death for women2. Due to modifications of
lifestyle and risk factors, and better stroke management,
the incidence of stroke in developed countries has de-
creased and its mortality has been reduced3,4. Neverthe-
less, the treatment of stroke is far from being satisfactory.
Over the past decade, acute stroke has finally been rec-
ognized as a medical emergency4,5. World Federation of
Neurology Research Group on Organization and Deliv-
ery of Neurological Services has published recommenda-
tions for prevention of cerebrovascular diseases.6 Also,
acute stroke treatment, primary and secondary prevention,
and rehabilitation at specialized wards have been proved
to be effective7-11. In the past year, several recommenda-
tions for stroke management were published12-22. These
are recommendations proposed by the Croatian Society
for Neurovascular Disorders of the Croatian Medical As-
sociation; University Department of Neurology, Sestre
milosrdnice University Hospital, which is the Reference
Center for Neurovascular Disorders of the Croatian Min-
istry of Health;  and the Croatian Stroke Society.
We provide an overview of the already accepted thera-
peutic strategies and an evaluation of the evolving new
ones.
Table 1 summarizes definitions of the levels of evi-
dence.
PART I PRIMARY PREVENTION
Primary prevention is aimed at reducing the risk of
stroke in asymptomatic people. Lifestyle and several
medical conditions have been identified so far as risk fac-
tors for stroke. These include eating and drinking habits,
smoking, physical activity, hypertension, diabetes melli-
tus, elevated cholesterol levels, myocardial infarction, atrial
fibrillation, and carotid stenosis.
Lifestyle
A report from the Framingham Study(23) indicates
that an increased daily consumption of fruits and veg-
etables may decrease the risk of stroke, including hemor-
Table 1. Levels of evidence and classes of recommendations
Level I: high level of evidence Source a: primary endpoint from randomized, double-blind study with
sufficient sample size
Source b: properly performed meta-analysis of qualitatively outstanding
randomized trials
Level II: intermediate level of evidence Source a: randomized, non-blind studies
Source b: small randomized trials
Source c: predefined secondary endpoints of large randomized trails
Level III: low level of evidence Source a: a prospective case series with concurrent or historical control
Source b: post hoc analyses of randomized trials
Level IV: undetermined level of evidence Source a: small case series without control, case reports
Source b: general agreement despite the lack of scientific evidence
from controlled trials
rhagic stroke. Physical activity is inversely related to the
risk of stroke. A prospective cohort study24 of male par-
ticipants in the Physician Health Study has revealed that
vigorous exercise is associated with a decreased risk of
stroke. This association is mediated through beneficial
effects on body weight, blood pressure, serum cholesterol
and glucose tolerance. Apart from these effects, physical
activity has shown no direct influence on stroke incidence.
Cohort studies have isolated cigarette smoking as an
independent risk factor for ischemic stroke in both men25
and women26. The risks are directly dependent on the
consumption of cigarettes and may be as high as 6-fold
compared with non-smokers. In both studies, the subjects
who had stopped smoking considerably reduced the risk
of stroke, i.e. by 50%27.
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A recent case-control study27 has suggested that mod-
erate alcohol consumption (up to two drinks of liquor, two
cans of beer, or two glasses of wine per day) would decrease
the risk of ischemic stroke. On the contrary, heavy alco-
hol consumption is associated with an increased risk of
both ischemic and hemorrhagic stroke27.
Stress reaction enhances platelet aggregation. It also
activates the renin-angiotensin system and production of
angiotensin II leading to a rise in arterial blood pressure.
Stress causes higher incidence of cardiovascular and cere-
brovascular disorders28-30. However, only scarce data exist
on the direct connection of stress and stroke31-37. Most of
these studies are difficult to compare due to different popu-
lation, different design and due to difficulties in the defi-
nition of stress. However, data from these studies could
indicate that stress is especially associated with a higher
incidence of hemorrhagic stroke. The risk of stroke in gen-
eral and of ischemic stroke in oral contraceptive (OC) us-
ers in particular increases with higher estrogen content of
OCs38. Whether low dose OCs carry a risk is still being
debated, since the present data indicate no increase in the
risk in the USA39, a slightly increased risk in Europe, and
a threefold risk in Africa, Asia and Latin America40. Such
data may be due to either a high prevalence of hyperten-
sion and smoking in the non-USA countries, or to some
other unknown factors. In the WHO study conducted in
developing countries41, the risk of cerebral hemorrhage was
significantly increased among OC users in general. The risk
was proven higher with high-dose OCs. It also significantly
increased with age (>35 years) and other associated risk
factors such as hypertension and smoking. OC use is also
associated with a small increase in the risk of subarachnoi-
dal hemorrhage (SAH). This increase is marginal with low-
estrogen preparations but is strongly increased with con-
comitant hypertension38.
There are numerous observational studies of postmeno-
pausal hormone replacement therapy (HRT) and stroke
risk42-43. Unfortunately, due to a selection bias that refers
to the fact that women prescribed and taking HRT differ
in many known and unknown ways from those who do not
use HRT, the results cannot be taken as conclusive.
The use of cocaine, especially alkaloidal forms (“crack”),
has been associated with an increased occurrence of cere-
brovascular disease44, both ischemic and hemorrhagic forms.
Hypertension
Hypertension is the most prevalent and modifiable
risk factor for stroke today, and its treatment substantially
reduces the risk of stroke. A meta-analysis of 14 random-
ized trials has shown that a decrease in diastolic blood
pressure by merely 5-6 mm Hg in hypertensive patients
equals a 42% reduction in stroke incidence45.
The Systolic Hypertension in the Elderly Program
(SHEP)46 has revealed that the management of isolated
systolic hypertension (greater than 160 mm Hg) in patients
older than 60 reduces the total incidence of stroke by 36%,
and of ICH alone by 50%47.The absolute benefit, estimated
for a 5-year period, was 30 events per 1000 participants46.
The optimal blood pressure has not yet been confirmed, but
there is some concern that a vigorous reduction in blood
pressure might be associated with an increased cardiovas-
cular morbidity.
Recently, a reduction in stroke risk was observed in a
randomized placebo-controlled trial of an angiotensin-
converting enzyme (ACE) inhibitor in a group of high-
risk patients that included both hypertensive and non-
hypertensive individuals9.
Diabetes mellitus (DM)
Although DM has been recognized as an independent
risk factor for ischemic stroke, it has not yet been estab-
lished whether strict control of blood glucose can be a fac-
tor in stroke prevention. In fact, in patients with type 2
DM, intensive sulphonylurea and/or insulin therapy ame-
liorated microvascular systemic complications, but not
macrovascular ones such as stroke48.
Hypercholesterolemia
Although former trials49 did not find strong association
between serum cholesterol levels and stroke, two large stud-
ies50-51 have demonstrated that statins (pravastatin and sim-
vastatin) can decrease the risk of stroke for patients with co-
ronary heart disease (CHD). The CARE study has revealed
a 32% reduction in the relative risk of stroke with prava-
statin therapy52, and a 24% reduction (28% reduction in
cerebrovascular events · stroke and TIAs) with simvastatin
in the 4S study53. A recent meta-analysis including data
from the above trials confirmed a total of 31% reduction in
all stroke forms, except for those with fatal outcome54.
Antithrombotic drugs
Numerous studies have proven aspirin efficacy as a se-
condary prevention agent8. Only a few studies have ever
Recommendations for stroke management
Acta clin Croat, Vol. 40, No. 2, 2001 131
focused on aspirin as a primary prevention device. In the
non-blind British male physician study55, 5139 physicians
were randomly allocated to receive or not receive 500 mg
of aspirin daily. There was no difference in the incidence
of myocardial infarction (MI), but disabling strokes were
more common among those allocated to aspirin. The higher
incidence of stroke in the aspirin group was probably due
to the higher incidence of hemorrhagic stroke. The
Physician’s Health Study56 that included 22 071 male phy-
sicians receiving either 325 mg of aspirin or placebo every
other day in a randomized double blind, placebo controlled
study has shown a 44% risk reduction of MI and a non-
significant increase in the risk of stroke. In the subgroup
with hemorrhagic strokes, aspirin was associated with an
increased risk, with a statistical borderline significance.
In the Nurses’ Health Study cohort57, in which the in-
cidence of stroke in women taking aspirin was monitored,
the women taking aspirin had a smaller relative risk of MI,
but no alteration in the risk of stroke.
Surgery
The Asymptomatic Carotid Atherosclerosis Study
(ACAS)58 reports that patients with an asymptomatic
carotid stenosis greater than 60% had a 5-year relative risk
reduction of 53% of ipsilateral stroke if carotid endarter-
ectomy (CEA) was performed. However, the absolute risk
reduction was small (5.9% strokes in five years), as was the
rate of ipsilateral stroke in the medically treated group
(11.0% strokes in five years, or 2.3% annually). These re-
sults were assessed with a joint perioperative mortality and
morbidity rate of 2.3%. Notably, the rate of complications
was 2- to 3-fold when carotid endarterectomy was per-
formed as a secondary prevention procedure59-60.
Recommendations
1. Cigarette smoking should be discouraged (Level II).
2. Heavy use of alcohol should be avoided, whereas mod-
erate consumption should be permitted (Level II).
3. Regular physical activity is recommended (Level II).
4. Increased consumption of fruits and vegetables is rec-
ommended (Level III).
5. It is recommended to avoid stress or to learn how to
cope with it (Level IV).
6. Avoid high estrogen content of OCs, and avoid OCs
in all women older than 35 with concomitant hyper-
tension or smoking habit (Level II).
7. Avoid cocaine (Level IV).
8. Treatment of hypertension is strongly recommended
as the most effective means of decreasing morbidity
and mortality due to either ischemic or hemorrhagic
stroke (Level I). Blood pressure should be kept below
140/85 mm Hg by means of lifestyle modifications
and/or pharmacological treatments.
9. Although strict control of glucose levels in DM and
high cholesterol levels have not yet been proven to be
associated with a decreased risk of stroke in general,
it should be encouraged because of the benefits in
terms of other diseases (Level III).
10. In coronary patients, statin treatment clearly reduces
the risk of stroke (Level II). Statins should be pre-
scribed in patients with CHD and high or moderate
cholesterol levels. The benefits of statins probably ex-
tend to patients with stroke and high cholesterol lev-
els.
11. There is no scientific support for prescribing aspirin
to reduce the risk of stroke in asymptomatic patients
(Level I). However, aspirin will reduce the risk of MI
in an asymptomatic population.
12. Screening with ultrasound of the brain blood vessels
in patients with known risk factors is recommended61
(Level III).
13. CEA is not recommended for patients with stenosis
lesser than 50% (Level I).
14. CEA should be performed in asymptomatic patients
with a low surgical risk (<3%) and with life expectancy
of at least 5 years (Level II), having stenosis 60%-99%
and in centers with joint perioperative complication
rate of stroke and death of less than 6% (Level I).
Anticoagulation
Atrial fibrillation (AF)
Atrial fibrillation is a common arrhythmia and an
important risk factor for stroke, with established effective
therapy for stroke prevention. The annual risk of stroke
in unselected patients with nonvalvular atrial fibrillation
is 5%, with a wide clinically important variation among
subpopulations of AF patients (0.5%-12% per year)20.
Aggregate analysis of several trials62 shows that oral an-
ticoagulation therapy with vitamin K antagonist, warfarin,
reduces the rate of ischemic stroke by 70% compared with
untreated patients (AFASAK, SPAF, BAATAF, CAFA,
SPINAF). Assessment of the optimal intensity of antico-
agulation therapy producing an INR (International Nor-
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malized Ratio) between 2.0 and 2.9 reduced the combined
incidence rate for both ischemic and hemorrhagic events
by 80% when compared with INR below 2.063. When
tested with INR above 5.0, the risk of bleeding became
unacceptable, whereas no significant reduction in throm-
boembolism was seen with INR below 2.0. The effect of
aspirin was assessed in four separate randomized trials64.
Aspirin yielded a pooled risk reduction of 21% compared
with placebo. In two of these trials, it was proved to be
significantly less efficacious than warfarin.
The median age of patients with AF is 75 years. The
Framingham Heart Study noted a dramatic increase in
stroke risk associated with AF with advancing age, from
1.5% for those aged 50-59 to 23.5% for those aged 80-8965.
In addition, AF was associated with an OR for death of 1.5
(95% CI 1.2 to 1.8) in men and 1.9 (95% CI 1.5 to 2.2) in
women after adjustment for other risk factors. Patients with
AF and no other cardiovascular disease aged less than 65
years are at such a low risk that they should not be treated
or should be treated with aspirin. Patients over 65 without
other risk factors may be considered as being at a moder-
ate risk and therapy could include warfarin or aspirin. The
dose of aspirin should be 300 mg a day, because this dos-
age proved effective in patients with AF.
For patients over 75 years of age, a lower target INR
of 2.0 (1.6-2.5) may be more sensible to prevent hemor-
rhage. However, this lower warfarin level has not been
established, and many scientists disregard age and accept
a higher INR target of 2.5. Also, there are other patients
in whom aspirin might be preferred to warfarin: history
of previous hemorrhage, over 80 years of age, unstable
anticoagulation control because of poor drug or clinical
compliance, history of uncontrolled hypertension (systolic
blood pressure >180 mm Hg or diastolic blood pressure
>100 mm Hg), alcohol abuse and liver disease 66. In these
patients, the risk of hemorrhage may be increased.
Recommendations (Table 2)
1. All patients at a high risk of stroke should be consid-
ered for long-term oral anticoagulation therapy (tar-
get INR 2.5; range 2.0-3.0) (Level I).
2. Patients aged less than 65 with no cardiovascular dis-
ease or patients who are unable to receive anticoagulants
should be prescribed aspirin 300 mg per day (Level I).
3. Patients over 65 years of age without risk factors could
be prescribed either anticoagulants or aspirin 300 mg
per day (Level III).
4. In patients over 75 years of age, warfarin may be used
as an option, with a lower INR (target INR of 2.0; range
1.6-2.5) to decrease the risk of hemorrhage (Level IV).
Table 2. Guidelines for atrial fibrillation management in primary prevention
Age <65 years, no risk factors Aspirin 300 mg/day
Age <65 years, with risk factors Warfarin (target INR 2.5; range 2.0-3.0)
Age 65-75 years, no risk factors Aspirin 300 mg/day or warfarin
Age 65-75 years, with risk factors Warfarin (target INR 2.5; range 2.0-3.0)
Age >75 years, with or without risk factors Warfarin (target INR 2.0; range 1.6-2.5)
PART II ORGANIZATION OF
STROKE CARE
Stroke as an emergency
Successful stroke care begins with recognizing the
stroke as a medical emergency like acute MI. There is a
widespread consensus among stroke physicians that the best
way to provide early stroke care is to call the emergency
medical team (EMT) immediately, and to be transported
to an institution where stroke care can be provided at an
appropriate level. Despite the high mortality and morbid-
ity rate of stroke, many patients and relatives neither rec-
ognize the symptoms of stroke nor realize that seeking
treatment is urgent. Various factors are responsible for this
delay in patient referral to the hospital, including poor
awareness of stroke by both the patient and the family, re-
luctance to seek emergency medical help, incorrect diagno-
sis by EMT, and stroke rating as a low emergency by EMTs
and family physician. These facts emphasize the need for
an ongoing educational program.
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The first level of education includes public educa-
tion67. Many patients and their relatives are not aware of
the patient having a stroke. Teaching the public to recog-
nize the symptoms and signs of stroke is one of the high-
est priorities in public medical education, and can be
achieved through mass media. The public needs to be-
come aware of two important facts: first, stroke is a treat-
able condition; and second, there is a legitimate need for
stroke victims to be urgently transported to stroke cen-
ters.
The second level of education includes physicians.
Primary contact with general practitioners may cause de-
lays and prevent the early institution of adequate the-
rapy66. Preventive and acute neurological training pro-
grams should be included in undergraduate education. For
graduate MDs, published guidelines or recommendations
(similar to this one) are to be introduced. Evidence need
to be actively channelled using multiple strategies such as
opinion leadership, academic detailing, computerized re-
minders, mass media campaigns, or performance feedback
such as audits of physician’s acquaintance with the prob-
lem67. Such campaigns would lead to better professional
education and motivation of all personnel included in
stroke management, from the emergency medicine phy-
sicians, nurses, general practitioners, family doctors, neu-
rologists, specialists of internal medicine, and geriatricians
to physiotherapists. Medical personnel should be trained
to recognize the acute presentations of ischemic stroke,
and should be able to cope with the early complications
of stroke. Emergency medical teams need to be trained to
conduct a focused neurological examination that includes
the level of consciousness, presence of focal weakness,
presence of seizure activity, and presence of aphasia or
other cognitive disturbances. Also, they should be trained
to obtain few important facts from the medical history
such as exact time of onset, fluctuations of condition, risk
factors. They should also be acquainted with the things
they should do and should not do in early stroke manage-
ment. It is particularly important that these profession-
als understand that they are highly valued and competent
partners in providing acute stroke care.
Referral
Stroke patients should be referred to specialized cen-
ters such as stroke units68. Minimum requirements of such
centers include 24-h availability of CT scanning facilities,
neurologists or other stroke physicians, presence of other
specialized personnel, and adherence to treatment and
management guidelines. Stroke centers or stroke units are
not stand-alone solutions. They can only work optimally
if a well-established referral and rehabilitation network is
available.This also includes cooperation with primary care
physicians in primary and secondary prevention.
For optimal acute stroke care, it is essential that all
stroke patients are immediately referred to the hospital
best equipped to provide such care. This is the reason for
establishing minimal facilities for centers dealing with
stroke. While all stroke patients seem to benefit from
stroke unit treatment, certain subgroups of patients will
especially benefit in intensive care units69. Triage is nec-
essary and recommended by the Stroke Council of the
AHA (American Heart Association), American College
of Physicians and European Ad Hoc Consensus Group.
Stroke units
Stroke care should take place in a stroke unit. A sys-
tematic review7 has shown an 18% reduction in mortal-
ity, and a 29% reduction in death occurrence or ADL de-
pendence. A 25% reduction in death occurrence or need
for institutional care was noticed in patients treated in a
stroke unit compared with those treated on a general
medical ward (Level I). In a large randomized Norwegian
trail70 of patient treatments in the acute and subacute con-
dition, mortality was reduced by 46% compared with gen-
eral ward treatment.
A stroke unit is established as a hospital unit or part
of a hospital unit that exclusively or nearly exclusively
takes care of stroke patients. The staff and the multidisci-
plinary approach to the management and care of stroke
patients characterize the stroke unit. The core disciplines
of such a team are: medicine, nursing, physiotherapy, oc-
cupational therapy, speech and language therapy, and so-
cial work. The optimal size of a stroke unit in terms of
beds has not yet been assessed. Stroke units with as little
as six beds have shown effectiveness.
All types of stroke patients benefit from the treatment
and rehabilitation in stroke units: males and females,
young and elderly, with no difference according to the
severity of stroke68. Stroke units are available in several
categories:
1. The acute stroke unit - is responsible for the admis-
sion of acute stroke patients and for the continuance
of early treatment for several days but usually less than
one week.
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2. The combined acute and rehabilitation stroke unit -
admitting patients acutely and providing continuing
treatment and rehabilitation for several weeks or
months if necessary.
3. The rehabilitation stroke unit - admits patients after
a delay of one or two weeks and continues treatment
and rehabilitation for several weeks or months if nec-
essary.
4. A mobile stroke team - a mobile team offering stroke
care and treatment of stroke patients at different
wards. Such teams are usually present in hospitals
where stroke units are not available.
Of these, only the combined acute and rehabilitation
stroke units and the rehabilitation stroke unit have proven
effective in terms of reduced mortality and handicap68-71.
Recommendations
1. Stroke patient should be treated in specialized stroke
units (Level I).
2. Stroke needs to be considered a medical emergency
that requires public education, a referral and treatment
network, and fast management.
3. In case stroke happens, the emergency medical team
should be called immediately. Patients should be trans-
ported by the emergency medical team as fast as pos-
sible to qualified centers.
Management in the emergency room (ER)
It is necessary to simultaneously assess vital and neu-
rological functions and begin with treatment of life-
threatening circumstances. The therapeutic window is
narrow, making time essential for prognosis. There is no
need to emphasize how important it is to ascertain the
form of stroke by physical and neurological examination
combined with diagnostic tests. This is the reason why a
stroke patient should be treated as a medical emergency,
even when having mild symptoms13,72,73. Early assessment
of stroke subtypes based on the physical and neurologi-
cal evaluation, as well as skilled use and interpretation of
diagnostic tests, are essential74.
Once in the hospital, the problem is not resolved and
delay may still occur due to the:
· Lack of neuroimaging facilities.
· Admission policies that require placement of patients
on general medical wards.
· Standpoint of low urgent level by hospital staff.
· Lack of treatment possibilities for stroke.
· Lack of a stroke specialist, such as a neurologist or
some other trained physician with expertise for treat-
ment of stroke in the emergency room.
To have a standard patient care endorsed, one must
have strict protocols of management. Some values should
be kept individualized, e.g., blood pressure or blood glu-
cose levels. Above all, the ABC (airway, breathing, circu-
lation) procedure must be used and arterial O2 saturation
evaluated using either pulse oximetry or ABGS. As soon
as possible, a venous line should be inserted and samples
for CBC, blood chemistry and coagulation factors taken.
This task divided between physicians and nurses ought to
be followed by a specialist’s targeted examination.
Questions to be answered in the early patient evalua-
tion are75:
· The existence of a life-threatening condition.
· The interval between onset of symptoms and admis-
sion.
· The presence of increased intracranial pressure (ICP).
· Concurrent underlying severe illness.
· What is the prognosis?
Emergency diagnostic tests
Diagnostic tests are needed to differentiate between
the different types of acute stroke (ischemic, brain hem-
orrhage, subarachnoid hemorrhage) or to rule out other
brain diseases (brain tumors). They are essential to obtain
an impression about the underlying cause of brain is-
chemia (cardiac or carotid disease, risk factors), to provide
a basis for physiological monitoring of the stroke patient,
and to identify concurrent diseases or involving compli-
cations of stroke that may influence prognosis.
Cranial computed tomography (CT)
Computed tomography is the most important initial
diagnostic test for assessment of cerebral hemorrhage and
for distinguishing cerebral infarction from other lesions
that may produce focal neurological signs (brain tumors,
infections or contusions and extradural/subdural hemato-
ma). CT signs of early ischemia can be detected as early
as 2 h after stroke onset76, but they may also develop later.
It is sometimes possible to visualize an arterial clot (hyper-
density in the affected artery) or occlusion, which may
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identify the underlying cause of the stroke12. The detec-
tion of early changes such as edema (swelling), hypoden-
sity or blurring of normal structures is possible in about
50%-60% of ischemic stroke patients that are examined
in the acute phase77. If present, these may indicate that
the ischemic injury is more serious. They are also associ-
ated with poor outcome and may predict hemorrhagic
transformation76.
Magnetic resonance imaging (MRI)
MRI is more sensitive, but it has not yet reached the
level of standard procedure in most centers. Modern MRI
techniques such as diffusion and perfusion MRI and ma-
gnetic resonance angiography (MRA) require major re-
sources that are currently not available in Croatia.
Cerebrospinal fluid (CSF) analysis
Lumbar puncture and CSF analysis may sometimes be
needed in dubious findings of CT scan or in vasculitis. It
may differentiate between subarachnoidal hemorrhage
and infection, and may be useful in patients with subara-
chnoidal hemorrhage and negative CT findings78,79. It is
necessary in centers with no possibility of CT scanning




It should be performed in all stroke patients because
of the high incidence of heart condition in stroke patients.
Stroke and acute myocardial infarction may occur at the
same time. Hemispheric stroke may cause dysrhythmias
and heart failures. Frequently, dysrhythmias are the cause
of embolic strokes.
Ultrasound studies
Several types of ultrasound equipment may be used in
stroke diagnosis. The B mode scan gives information on
the morphology of extracranial arteries, while Doppler
ultrasound can be used to visualize blood flow. Duplex and
color duplex machines combine both facilities. Trans-
cranial Doppler (TCD) ultrasound can be used to inves-
tigate the blood flow within the basal intracranial arter-
ies and other vessels that are not accessible to other meth-
ods81,82, and may even enhance drug therapy83.
In skilled hands, an ultrasound scan may suggest the
cause of stroke such as occlusion of the carotid, middle
cerebral or vertebrobasilar arteries and intra- or extrac-
ranial stenosis, or extracranial artery dissection in some
cases84-88. It may provide additional information on the
cause of stroke (emboli detection89, or visualization of
aneurysm). In SAH, it is inevitable in detection and mo-
nitoring of vasospasm90 and of therapeutic effect91.
Other ultrasound studies include transthoracic and
transesophageal echocardiography to screen for cardio-
genic emboli, but these tests are usually not performed in
the ER. However, it seems to be useful to have these stud-
ies available in the first 24 h after stroke onset.
Laboratory tests
Laboratory tests include CBC and coagulation param-
eters, electrolyte status, hepatic and renal function check,
and basic markers of infarction.
Recommendations
1. Cranial computed tomography (CT) is the most im-
portant diagnostic tool in patients with suspected
stroke.
2. Early evaluation of physiological parameters, blood
chemistry and hematology, and of cardiac function is
recommended in the management of acute stroke pa-
tients. This also includes ECG, pulse oximetry and
chest X-ray.
3. Ultrasound of extra- and intracranial vessels, modern
MR techniques, cardiac ultrasound and specific hema-
tologic and serologic tests for rare causes of stroke
should be performed early after stroke, but should not
delay general or specific treatment.
Recommendations for stroke management
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PART III ACUTE STROKE
MANAGEMENT
It can be said that therapy for acute stroke has three
pillars. The first group can be addressed as general therapy.
It deals with the management of all underlying serious
medical conditions that need to be revised immediately.
Then, there is specific therapy that is directed against as-
pects of stroke pathogenesis. It effects either recanalization
of the vessel occlusion or neuroprotection that is directed
against several mechanisms of neural injury that occurs after
brain ischemia. In hemorrhagic stroke, the mechanism of
bleeding is to be determined and considered for acute sur-
gical treatment. The third area of stroke treatment deals
with complications occurring as sequels of acute stroke.
These conditions can be divided into those of the neuro-
logic origin (secondary hemorrhage, space occupying
edema, seizures) and those not allied with neurologic con-
dition of the patient (infections, decubitus ulcers, deep vein
thrombosis or pulmonary embolism).
Monitoring of vital functions
To monitor vital functions and neurologic condition
accurately, frequent checks have to be made. Vital functions
of particular interest are: blood pressure, pulse rate, body
temperature, blood gases, and blood glucose levels. The
objective way to assess the neurologic status is the use of
neurological scales such as the NIH-Stroke Scale, Scandi-
navian Stroke Scale, Glasgow Coma Scale, and others.
Additional tests will have to be performed in some patients.
In patients with a pre-existing cardiac disease, history of
dysrhythmias and unstable blood pressure, on-line ECG
monitoring is recommended. To monitor the respiratory
action, cardiac electrodes or clinical evaluation can be used.
Most of the time, conventional blood pressure monitoring
proves adequate, however, when needed automatic inflat-
able units or mobile 24-h our blood pressure devices should
be available. Respiratory status is verified through pulse
oximetry or blood gases. Occasionally, central venous pres-
sure via central venous catheter will be indispensable in
specialized wards. The same catheter can also estimate other
information like intravascular volume, cardiac function and
compliance with the venous system.
GENERAL STROKE TREATMENT
It is not always neurological illness that is crucial for
the prognosis of  certain patients, but concurrent under-
lying medical conditions that are almost always present.
It has already been agreed upon “general treatment” as a
foundation for early stroke patient management13,17,22,72.
It includes respiratory and cardiac monitoring, blood pres-
sure control, treatment of elevated intracranial pressure,
fluid and metabolic management, metabolic surveillance
and fluid administration. Also, there is seizure treatment,
deep vein thrombosis and pulmonary embolism prophy-
laxis, infection control · especially aspiration pneumonia
and prevention of decubitus ulcers.
General stroke treatment is equally applied in special-
ized units as in general hospital wards. Despite this, the
prognosis for patients treated in stroke units is better when
early therapeutic actions are taken immediately.
Pulmonary function and airway protection
Normal respiratory function with adequate blood oxy-
genation is required for stroke management, primarily be-
cause of preservation of metabolic turnover in the marginal
zone of infarction, the so-called penumbra. Still, there are
no data obtained from prospective clinical trails to corrobo-
rate this assumption. Oxygenation of the blood is improved
by the administration of 2-4 l O2/min via a nasal tube.
In patients with seizures following hemispheric or
hemorrhagic stroke, a plugged airway may be present. In
patients with chronic obstructive airway disease, pulmo-
nary dysfunction may occur during exacerbation. Venti-
lation may be particularly compromised during sleep.
Early endotracheal intubation is recommended in the
event of a pathologic respiratory pattern. Stroke types that
may lead to this condition are: extensive vertebrobasilar
and hemispheric infarction, large intracranial hemor-
rhages, and unconscious patient at high risk of aspiration
pneumonia. The prognosis of stroke patients undergoing
intubation is thus better than usually thought, with a one-
year survival rate of almost one-third92,93. Before intuba-
tion, the general prognosis, coexisting life-threatening
medical conditions and patient family consent must be
considered and obtained.
Cardiac care
Cardiac arrhythmias may occur secondary to stroke.
Significant alterations in the ST segments and T wave on
ECG may appear in the acute phase and mimic myocar-
dial ischemia94. Cardiac enzymes may be elevated after
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stroke95. Every stroke patient should have an initial ECG.
However, not all cardiac phenomena after cerebral is-
chemia should be regarded as secondary. The coexistence
of myocardial infarction (MI) and stroke is possible, some-
times MI presents in the clinically silent form.
The main goal in stroke management is to obtain an
optimal cardiac output while maintaining a high normal
BP and normal heart rate. Central venous pressure should
be maintained at approximately 8-10 cm H2O. Central
venous pressure monitoring is valuable in the prevention
of volume deficiency or overload. The intravascular volu-
me must be kept stable. Dobutamine is an inotropic agent
with the advantage of increasing cardiac output without
major effect on heart rate or blood pressure. Dopamine
is useful in patients with hypotension or renal insuffi-
ciency. Increases in cardiac output may enhance cerebral
perfusion in the areas with autoregulative capacity break-
down due to cerebral ischemia.
Normal cardiac rhythm should be restored by drugs,
cardioversion or pacemaker care in cooperation with spe-
cialists of internal medicine or cardiologists.
Blood pressure (BP) management
BP monitoring and treatment are crucial. Many pa-
tients with acute infarcts have elevated BP. Cerebral per-
fusion in patients with advanced carotid stenosis depends
on mild hypertension. Blood flow autoregulation may be
defective in the areas of evolving infarction, and the flow
in the penumbra zone therefore becomes passively depen-
dent on the mean arterial pressure. A drop in BP must
therefore be avoided if an adequate cerebral perfusion
pressure is to be maintained. A target systolic BP of 180
mm Hg and diastolic BP of 100-105 mm Hg are recom-
mended in patients with prior hypertension. In other
cases, mild hypertension is desirable (160-180/90-100
mm Hg). Extremely high BP levels should be treated.
Systolic values over 220 mm Hg or diastolic values over
120 mm Hg are indications for early drug treatment
(Table 3). The reduction in BP should not be too vigor-
ous. There are only a few other indications for immedi-
ate antihypertensive therapy in the first hour after symp-
tom onset. Treatment may be appropriate in the setting
of acute myocardial ischemia (although extreme lowering
of BP is detrimental in patients with MI, cardiac insuffi-
ciency, acute renal failure, or acute hypertensive encepha-
lopathy). Non-ischemic causes of stroke, such as subarach-
noid hemorrhage or intracerebral hemorrhage, also are
indications for antihypertensive treatment.
The effects of oral nifedipine, still frequently used in
Europe and Croatia (due to the lack of span of iv treat-
ments) may be rapid and excessive. Its use is discouraged20.
Oral captopril (6.25-12.5 mg) or labetalol (10 mg) may be
used instead. Intravenous urapidil is being used increasingly
in this situation. Sodium nitroprusside is sometimes rec-
ommended despite some major side effects, such as reflex
tachycardia and coronary artery ischemia20.
Glucose metabolism
Many stroke patients are diabetics. Diabetes mellitus is
sometimes detected only after an ischemic infarction has
developed. Both hypoglycemia and hyperglycemia can have
unfavorable effects in patients with increased ICP. Serum
Table 3. Antihypertensive treatment in acute ischemic stroke
Systolic BP <220 mm Hg Do not treat
Diastolic BP <120 mm Hg
Systolic BP slightly increased when measured 15 min apart Nitroglycerin 5 mg IV or 10 mg po
Diastolic BP >120 mm Hg Sodium nitroprusside 1-2 mg iv (rarely needed)
Systolic BP <220 mm Hg Nifedipine 10 mg sl*
Diastolic BP 110-120 mm Hg Captopril 6.25-12.5 mg po
or Labetalol 5-20 mg iv**
Both when measured repeatedly Clonidine 0.15-0.3 mg iv or sc
Urapidil 10-50 mg iv followed by 4-8 mg/h iv
Dihydralazine 5 mg iv and metoprolol 10 mg iv
*Nifedipine may cause an overly rapid decline of BP
**Avoid in patients with asthma, cardiac failure, severe conduction abnormalities and bradycardia
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glucose level should be kept between 7.8 and 1096. There-
fore, temporary administration of insulin may be necessary.
A blood glucose of 10 mmol/l or higher requires immedi-
ate insulin titration. Unless the blood glucose is known, no
carbohydrate concentrate should be given to a stroke pa-
tient. Hypoglycemia may mimic acute ischemic infarction.
Hypoglycemia should be directly countered by an infusion
of 10%-20% glucose, preferably via a central venous line.
Body temperature
Fever negatively affects the neurologic stroke out-
come97,98. Infection is a risk factor for stroke, and many
patients develop an infection after stroke99. Fever increases
the infarct size, due to enhanced metabolism and greater
production of toxic amino acids. Therefore, elevated tem-
perature (>37.5 °C) in stroke patients should be treated
although there are no prospective data to support this
concept. Antipyretics such as paracetamol and early use
of antibiotics are usually recommended in case of appar-
ent bacterial infection.
Fluid and electrolyte management
In hemorrhagic stroke or SAH, serious electrolyte
abnormalities are frequent. Contrary, in ischemic stroke
they can rarely be found. A balanced fluid and electrolyte
status should be kept to avoid plasma volume contraction,
raised hematocrit, and impairment in the blood rheologic
properties. Electrolytes should be monitored daily and
substituted accordingly. Uncontrolled volume replacement
may increase cerebral edema, or lead to pulmonary edema
and cardiac failure. A venous approach is needed for ini-
tial fluid management and blood sampling. If larger vol-
umes of fluids need to be replaced or solutions with high
osmolality are used, placement of a central venous cath-
eter is recommended.
Recommendations
1. Neurological status and vital functions should be
monitored.
2. Glucose and body temperature should be monitored
and corrected, if elevated (Level III).
3. Monitoring and correction of electrolyte disturbances
are advised.
4. Secure airways and oxygen to patients with severe
acute stroke (Level III).
5. Do not treat hypertension in patients with ischemic





Thrombolytic therapy with recombinant tissue plas-
minogen activator (rt-PA), 0.9 mg/kg body weight given
within 3 h after stroke onset to patients with acute is-
chemic stroke) significantly improves the outcome of
stroke100. There is evidence that thrombolysis may also
work up to 6 h after stroke onset in carefully identified
patients101. In Europe, doubt about its risk-benefit ratio
exists, which is preventing some centers from actively pro-
moting the treatment. Caution is advised before giving in-
travenous rt-PA to patients with severe stroke (NIH
Stroke Scale >22) and extended early infarction signs102.
In centers where thrombolytic therapy is offered, it should
only be given if a physician who has expertise in the di-
agnosis of stroke has established the diagnosis (Table 4).
Secondly, brain CT should be assessed by physicians who
have expertise in identifying major early infarct signs,
which may represent a contraindication for iv thromboly-
sis. Thrombolytic therapy should not be given unless the
emergency ancillary care and the facilities to handle bleed-
ing complications are readily available.
Table 4. Indications for thrombolytic treatment with rt-PA
1 Ischemic stroke within 180 minutes
2 NIHSS of neurologic deficit
3 CT brain scan without intracranial bleeding
4 Age >18 years
Due to the high risk of major bleeding and possible risk
of death, the risks and potential benefits of rt-PA should
be discussed with the patients and their families before the
treatment is initiated. Recognition of early infarct signs and
strict adherence to exclusion criteria (Table 5) are essential.
Intravenous streptokinase has been shown to be asso-
ciated with an unacceptable risk of hemorrhage and
death103-106. Its use is strongly discouraged.
Intra-arterial thrombolytic therapy with prourokinase
was associated with better outcome10. The treatment is
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only available in selected centers and requires superselec-
tive angiography107.
Intra-arterial treatment with urokinase or rt-PA sho-
wed good results in acute basilar occlusion (107,108). It is
available in selected centers. Due to the small number of
basilar occlusions, no randomized trials have been con-
ducted.
Table 5. Contraindications for rt-PA thrombolytic treatment
1 Brain CT signs of intracranial hemorrhage
2 Brain CT or MR signs of acute stroke
3 Small (NIHSS <4) or large (NIHSS >22) neuro-
logic deficit or quick symptom regression
4 Clinical evidence of SAH, but brain CT negative
5 History of intracranial bleeding, arteriovenous mal-
formations, aneurysm or brain tumor
6 Stroke or head trauma within 3 months
7 Systolic BP <185 mm Hg or diastolic BP >110 mm
Hg
8 Arterial catheterization at the site that is not com-
pressible or lumbar puncture within a week
9 Operation or major injury within two weeks
10 Gastrointestinal bleeding or urinary tract bleeding
within three weeks
11 Platelets >100 000
12 APTV exceeding control values due to heparin
treatment within 48 hours
13 Oral anticoagulation treatment, PV >15 or INR
>1.7
14 Seizure as initial stroke presentation
15 Glucose levels <2.78 or  >22.2 mmol/l




Ancrod, a defibrinogenating enzyme, has been shown
to improve outcome after acute ischemic stroke, if given
within 3 h after stroke onset and over 5 days110.
Recommendations for centers offering
thrombolysis
1. Intravenous rt-PA (0.9 mg/kg; maximum of 90 mg)
with 10% of the dose given as a bolus, followed by an
infusion over 60 min, is recommended within 3 h of
onset of ischemic stroke (Level I), if indications and
contraindications are strictly followed (Tables 4 and 5).
2. The benefit from the use of iv rt-PA for acute ischemic
stroke between 3 and 6 h from stroke onset is only
present in selected patients (Level I).
3. Thrombolysis with iv rt-PA is not recommended
when the time of stroke onset cannot be determined;
this includes patients whose strokes are recognized
upon awaking.
4. Thrombolysis with iv streptokinase, outside the set-
ting of a clinical investigation, is dangerous and not
indicated for the management of patients with is-
chemic stroke (Level I).
5. Thrombolysis with other iv drugs is not recommended
due to insufficient data.
6. Intra-arterial treatment of acute middle cerebral artery
M1 occlusion in a 6-h time window using prourokinase
results in a significantly improved outcome (Level I).
7. Acute basilar occlusion may be treated with intra-ar-
terial therapy in selected centers (Level IV).
8. Ancrod given in a 3-h time window significantly im-
proves outcome after acute ischemic stroke (Level I).
Platelet inhibitors
Two large randomized, non-blind, intervention stud-
ies118,111 have shown that aspirin given within 48 h after
stroke reduces mortality and recurrent stroke minimally, but
statistically significantly. Up to now, it is not clear if the
positive effect of early aspirin is due to the effect on the
infarct itself or to the prevention of recurrent infarction. A
recent meta-analysis112 has shown that the prompt use of
aspirin should be routinely considered for all patients with
suspected acute ischemic stroke (even when CT scan is not
available), mainly to reduce the risk of early recurrence.
Early anticoagulation
Although early heparin treatment has been fre-
quently used in the treatment of acute ischemic stroke,
it has not proved overall benefit due to the higher rate
of hemorrhagic complications. None of the trials per-
formed over the past years has proved the influence of
heparin on stroke outcome or recurrent stroke reduc-
tion113. Also, low-molecular-weight heparins and
heparinoids (LMWHs) were analyzed in a systematic
meta-analysis114. LMWHs reduce venous thromboem-
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bolic events in patients with acute ischemic stroke and
increase the risk of extracranial bleeding. A nonsignifi-
cant reduction in combined death and disability, and
nonsignificant increases in case fatality and symptom-
atic intracranial hemorrhage were also observed. There
is a general agreement that heparins should not be used
in the routine management of patients with ischemic
stroke. Most investigators agree that heparin is only in-
dicated in selected patients (Table 6). Contraindications
for treatment with heparin include large infarcts (>50%
MCA territory), uncontrollable arterial hypertension,
and advanced microvascular changes in the brain.
Table 6. Indications for heparin treatment after stroke
1 Stroke due to cardioembolism with high risk of re-
embolization (artificial valves, atrial fibrillation, MI
with
mural thrombi, left atrial thrombosis)
2 Coagulopathies such as protein C and S deficiency,
APC-resistance
3 Symptomatic dissection of extracranial arteries
4 Symptomatic extracranial and intracranial stenosis
5 Symptomatic internal carotid stenosis prior to opera-
tion
6 Crescendo TIAs or stroke in progression
7 Sinus venous thrombosis
Hemodilution
There is no proof of hemodilution therapy as clinically
beneficial. At the same time, a possibility of excess brain
edema exists making the decision difficult93,115-117.
Neuroprotection
There is no proof that any neuroprotective agent in-
fluences stroke outcome118,119. There is no recommenda-
tion to treat ischemic stroke patients with neuroprotec-
tive agents.
Recommendations
1. There is no recommendation for general use of hep-
arin, low molecular heparin or heparinoids after is-
chemic stroke (Level I).
2. Full dose heparin may be used in selected indications
(Table 6) (Level IV).
3. Aspirin (100-300 mg per day) may be given after
stroke to an unselected population, even without CT
scan (Level I).
4. Hemodilution therapy is not recommended in the
management of ischemic stroke patients (Level I).
5. Neuroprotective drugs are not recommended in is-
chemic stroke patients (Level I).
SPECIFIC TREATMENT IN
HEMORRHAGIC STROKE
The classic presentation of intracerebral hemorrhage
(ICH) is sudden onset of a focal neurologic deficit that
progresses over minutes to hours with accompanying
headache, nausea, vomiting, decreased consciousness and
elevated blood pressure. The early progression of the neu-
rologic deficit in many patients with ICH is frequently
due to the ongoing bleeding and enlargement of the he-
matoma during the first few hours120.
Specific treatment is oriented to determination of
bleeding mechanisms and the possibility of surgical treat-
ment. Clinicians try to determine the likely cause of the
hemorrhage according to its location in the brain as seen
on the CT scan, the presence of structural abnormalities as
seen in brain imaging, associated medical conditions such
as hypertension, and the patient’s age. Hemorrhages that
originate in the putamen, globus pallidus, thalamus, inter-
nal capsule, deep periventricular white matter, pons and cer-
ebellum, particularly in a patient with known hypertension,
are often attributed to hypertensive small-vessel disease.
Contrary, lobar hemorrhages in the very old subjects are
often thought to be due to amyloid angiopathy. These as-
sumptions may be incorrect. A majority of patients with
lobar hemorrhage have hypertension. Some vascular mal-
formations may also be the cause of deep lobar hemorrhage.
If angiography is to be done, the timing will depend on the
clinician’s judgment. It is dependent of the clinical condi-
tion of the patient and the neurosurgeon’s judgment of
surgical emergency, if surgery is really needed.
Magnetic resonance imaging (MRI) and magnetic
resonance angiography (MRA), if available, have emerged
as additional useful tools for detecting structural abnor-
malities such as malformations and aneurysms120. Al-
though MRI may miss small aneurysms and vascular
malformations, it is superior to CT and angiography in
detecting cavernous malformations. Angiography is still
the gold standard in detecting aneurysms.
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Recommendations
1. Angiography should be considered for all patients
without a clear cause of hemorrhage who are surgical
candidates, particularly young, normotensive patients
who are clinically stable (Level IV).
2. Angiography is not required for older hypertensive
patients who have a hemorrhage in the basal ganglia,
thalamus, cerebellum or brain stem, and in whom CT
findings do not suggest a structural lesion. Most eld-
erly patients with deep hemorrhage die or have severe
morbidity related to the hemorrhage and are not can-
didates for angiography (Level IV).
3. Timing of cerebral angiography depends on the pa-
tient’s clinical condition and the neurosurgeon’s judg-
ment concerning surgical emergency, if surgery is re-
ally needed.
4. MRI and MRA are helpful and may obviate the need
for contrast cerebral angiography in selected patients.
They should also be considered when searching for
cavernous malformations in normotensive patients
presenting with lobar hemorrhages and normal angio-
graphic results, who are surgical candidates (Level IV).
Medical management
Four small randomized trials of medical therapy for
ICH have been conducted116,121,123,126: steroid versus pla-
cebo treatment122,123), hemodilution versus best medical
therapy116, and glycerol versus placebo123. None of the 4
studies has shown any significant benefit for the three
therapies. In the study testing steroids121, patients who
were treated with steroids were more likely to develop
infections than those treated with placebo.
Recommendation
1. Corticosteroids are not recommended due to possible
side effects and increased development of secondary
infections (Level II)
Vasospasm after SAH
Cerebral vasospasm is a delayed narrowing of large
capacity arteries at the base of the brain after SAH, of-
ten associated with radiographic or cerebral blood flow
evidence of diminished perfusion in the distal territory of
the affected artery. Angiographic vasospasm has a typi-
cal temporal course, with onset 3 to 5 days after the hem-
orrhage; maximal vasospasm is expected at 5 to 14 days,
and gradual resolution over 2 to 4 weeks124. In about one
half of cases, vasospasm is manifested by the occurrence
of a delayed neurologic ischemic deficit, which may re-
solve or progress to cerebral infarction (with acute or sub-
acute development of focal or generalized symptoms)125.
The incidence of angiographic vasospasm is over 50%,
with symptomatic vasospasm in 32% of patients126.
Therefore, TCD is a valuable tool for detection of vasos-
pasm and timing of angiography.
Recommendation
1. Nimodipine is recommended to reduce poor outcome
related to vasospasm, while complications and side
effects of the drug are minimal (Level I)127,128. Other
calcium antagonists given orally or intravenously are
of uncertain value (Level I)129,130.
2. Worse hypertension, hypervolemia and hemodilution
are recommended for prevention and treatment of is-
chemic complications from vasospasm (Level III)131,132.
3. Intracisternal fibrinolysis and antioxidant and anti-
inflammatory agents are of uncertain value (Level
III)133.
4. Transluminal angioplasty is recommended for the
treatment of vasospasm in patients in whom conven-
tional therapy has failed (Level IV)134,135.
Hyponatremia/Volume contraction
The reported incidence of hyponatremia following
SAH ranges from 10% to 34%. It usually develops several
days after the hemorrhage (3rd to 15th day after SAH) and
is more common in patients with poor clinical grade136.
Hyponatremia has been attributed to inadequate secretion
of antidiuretic hormone. Hyponatremia lowers the level of
consciousness, leads to muscular weakness, seizures and
coma. Dehydration along with hypotension increases the
risk of vasospasm137. Although the incidence of hyponatre-
mia was not altered by the administration of large volumes
of fluid or of fludrocortisone138, hyponatremia is usually too
mild to produce symptoms. Therefore, aggressive measures
to correct hyponatremia appear unwarranted, especially if
they lead to volume contraction.
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Recommendations
1. Management of hyponatremia after SAH is recom-
mended to emphasize the need to prevent volume
contraction; management should include intravascu-
lar administration of isotonic fluids (Level III).
2. Hypotonic fluids should be avoided as they may con-
tribute to hyponatremia; fluid restriction should not
be instituted to treat hyponatremia (Level IV).
Surgical therapy
Hematoma treatment
The ideal goals of surgical treatment of ICH should
be to remove as much blood clot as quickly as possible
with the least amount of brain trauma from the surgery
itself. If possible, surgery should also remove the under-
lying cause of ICH, such as an arteriovenous malforma-
tion, and prevent complications of ICH such as hydro-
cephalus and mass effect of the blood clot. The decision
on when and what to operate still remains controversial
due to the lack of data from randomized clinical trials. So
far, there is an overall agreement based on the evidence
available from known researches19.
Recommendations
1. Patients with small hemorrhages (<10 cm3) or mini-
mal neurologic deficit should not be surgically treated
(Level II).
2. Patients with a GCS score <4 should not be surgically
treated (Level II). However, these patients will be sur-
gical candidates if they have simultaneous cerebellar
hemorrhage within brain stem.
3. Patients with cerebellar hemorrhage >3 cm who are
neurologically deteriorating or who have brain stem
compression and hydrocephalus from ventricular ob-
struction should have surgical removal of the hemor-
rhage as soon as possible (Level III).
4. ICH associated with a structural lesion such as an
aneurysm, arteriovenous malformation or cavernous
angioma may be removed if the patient has a chance
for good outcome and the structural vascular lesion is
surgically accessible (Level III).
5. Young patients with a moderate or large lobar hem-
orrhage who are clinically deteriorating (Level II).
Hydrocephalus
The etiology of acute ventriculomegaly after SAH is
usually obstructive hydrocephalus caused by intraventricu-
lar blood. Acute hydrocephalus (ventricular enlargement
within 72 hours) is noted in 20%-27% of patients surviv-
ing the ictus of SAH, with a greater frequency among
poor-grade patients. Ventriculostomy has been associated
with an increased rate of recurrent hemorrhage after SAH
and may also be complicated by meningitis/ventriculi-
tis139,140. Chronic ventriculomegaly occurs in 14%-60% of
patients within 30 days from SAH141.
Recommendations
1. Acute (obstructive) hydrocephalus ventriculostomy is
recommended, although it may be associated with in-
creased recurrent hemorrhage and infection (Level
IV).
2. Chronic (communicating) hydrocephalus is a frequent
occurrence after SAH. Temporary or permanent cere-
brospinal diversion is recommended in symptomatic
patients (Level IV).
Surgical treatment of aneurysm
Recommendations
1. Surgical clipping is recommended to reduce the rate
of rebleeding after aneurysmal SAH (Level III)142.
2. Early referral to specialized centers is recommended.
Early surgery reduces the risk of recurrent hemorrhag-
ing after SAH and is recommended for the good grade
patient (Hunt and Hess 1 or 2) with uncomplicated
aneurysm. For other clinical situations, either early or
delayed surgery is recommended, depending on the
specific clinical situation (Level II)143,144.
3. Complete surgical obliteration of the aneurysm is rec-
ommended whenever possible, since wrapped or
coated aneurysms or incompletely clipped aneurysms
probably have an increased risk of recurrent hemor-
rhage (Level IV)145.
Measures of prevention of recurrent hemorrhage after SAH
Recommendations
1. Regulated bed rest or antihypertensive therapy both
are frequently included in overall treatment of patients
with SAH; these measures should be combined with
other definitive measures to prevent recurrent hemor-
rhage (Level I)146.
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2. Carotid ligation is of indeterminate value in prevent-
ing rebleeding (Level I)147.
3. Antifibrinolytic therapy to prevent recurrent hemor-
rhage is recommended in certain clinical situations,
e.g., patients with a low risk of vasospasm and/or ben-
eficial effect of delaying surgery (Level I). However,
antifibrinolytic therapy has been associated with a
higher rate of cerebral ischemia, resulting in no ben-
efit in terms of overall outcome. Future studies are
recommended to determine whether a combination of
antifibrinolytic therapy with other treatments to re-
duce vasospasm will be beneficial.148.
4. Intraluminal coils and balloon-coils can promote an-
eurysmal thrombosis in a majority of cases, although
long-term occlusion remains indeterminate149.
Treatment of increased intracranial pressure (ICP)
and brain edema
Ischemic brain edema
Cytotoxic brain edema occurs during the first 24-48
h after ischemic infarcts. In younger patients, brain edema
and elevated ICP may become a major complication and
may lead to herniation and death150. These patients usu-
ally show a rapid decline in consciousness and develop
signs of herniation 2-4 days after the onset of symptoms.
Outcome is fatal in the majority of these patients, with a
mortality of about 80% with standard treatment150,151.
Medical therapy
The basic management of elevated intracranial pres-
sure following stroke includes 30° upright position and the
patients should not be turned to either side during the first
24 h.The level of sedation must be controlled and adjusted
if necessary to avoid pain and anxiety. Body temperature
should be normalized. Osmotherapy with intravenous
mannitol (25-50 g every 3-6 h) is the first medical treat-
ment to be used if the signs of space-occupying edema
occur. It should not be given for longer than 2 days or in
emergency situations (for example, decompensated ICP).
Mannitol is cleared by the kidney and acts as an osmotic
diuretic. Electrolyte disturbance and hypovolemia are
complications of osmotherapy with mannitol. During
osmotherapy, plasma osmolality should not exceed 330
mOsm/kg. Short-term increases of osmolality seem to be
more effective in reducing ICP compared with continu-
ous high osmolality. Osmotherapy is only effective for 48-
72 h. Hypotonic and glucose-containing solutions should
be avoided as replacement fluids. Dexamethasone and
other corticosteroids are not useful for brain edema treat-
ment after stroke.
Intravenous barbiturates can decrease ICP by lower-
ing cerebral blood volume. A parallel decrease in the mean
arterial pressure may lead to a decrease of the cerebral
perfusion pressure. Therefore, an effective therapy with
barbiturates depends on reliable on-line monitoring of
ICP and mean arterial pressure. The injection of barbi-
turate is stopped when a burst-suppression pattern is
reached75.
Decompressive surgery
Malignant middle cerebral artery (MCA) infarction
Space-occupying hemispheric infarction, the so-
called malignant MCA infarction, has a high mortality
and morbidity even with optimal conservative treatment.
More than 80% of these patients die despite maximal
conservative treatment. In selected cases, hemicraniec-
tomy may be lifesaving and may improve outcome150,151.
Cerebellar infarction
Cerebellar territorial infarction has a good clinical
course even without aggressive treatment. However, in
some cases with space-occupying cerebellar infarction, co-
matose patients have a mortality of about 80% if treated
conservatively. This mortality is due to the development of
occlusive hydrocephalus or direct brainstem compression.
In these patients, decompressive surgery of the posterior
fossa is significantly superior to ventriculostomy151,152. It
should be noted that these are the results of open small- or
medium-sized case series, so data from a controlled, ran-
domized trial are needed.
Recommendations
1. Osmotherapy is recommended for patients whose
condition is deteriorating secondary to increased in-
tracranial pressure, including those with herniation
syndromes (Level III).
2. Surgical decompression and evacuation of large cer-
ebellar infarction compressing the brain stem is justi-
fied (Level III).
3. Surgical decompression and evacuation of a large
hemispheric infarction can be a lifesaving measure.
Survivors may have a residual neurologic deficit that
allows an independent life (Level III).
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Hemorrhagic brain edema
Osmotherapy
The first medical line of defense is osmotherapy. How-
ever, it should not be used prophylactically. Mannitol 20%
(0.25-0.5 g/kg every 4 h) is reserved for patients with type
B ICP waves, progressively increasing ICP values, or clini-
cal deterioration associated with mass effect. Due to re-
bound phenomenon, mannitol is recommended for only
≤5 days. To maintain the osmotic gradient, furosemide (10
mg for 2-8 h) may be administered simultaneously with
osmotherapy. Serum osmolality should be measured twice
a day in patients receiving osmotherapy and targeted to
≤310 mOsmol/L.
Hyperventilation
Hypobaria causes cerebral vasoconstriction. Reduction
of cerebral blood flow is almost immediate, although peak
ICP reduction may take up to 30 minutes after pCO2 has
changed. Reduction of pCO2 to 35-30 mm Hg, which is
best achieved by raising ventilation rate at a constant tidal
volume (12-14 ml/kg), lowers ICP by 25%-30% in most
patients.
Muscle relaxants
Neuromuscular paralysis in combination with ad-
equate sedation can reduce elevated ICP by preventing
increases in intrathoracic and venous pressure associated
with coughing, straining, suctioning, or “bucking” the
ventilator (Level III). Nondepolarizing agents such as
vecuronium or pancuronium with only minor histamine
liberation and ganglion-blocking effects are preferred in
this situation. Patients with critically elevated ICP should
be pretreated with a bolus of a muscle relaxant before air-
way suctioning.
Sedation
Many patients who are delirious or stuporous are agi-
tated. Hyperactivity is distressing to patients and may lead
to self-injury or may increase ICP. Prudent use of minor
and major tranquilizers is recommended, e.g., short-act-
ing benzodiazepines or propofol19. Analgesics and neuro-
leptics can be added if necessary.
Recommendations
1. Osmotherapy with mannitol is reserved for patients
deteriorating due to severe brain edema (Level IV).
2. Steroids are avoided because multiple potential side
effects exceed the potential benefit (Level II).
3. Hyperventilation at constant tidal volume is recom-
mended to lower ICP (Level III).
4. Muscle relaxants in combination with sedation are
recommended to reduce increased ICP by preventing
increases in intrathoracic and venous pressure associ-
ated with coughing, straining, suction or “bucking” the
ventilator (Level III).
PREVENTION AND TREATMENT OF
POST-STROKE COMPLICATIONS
Aspiration and pneumonia
One of the most important risks in the early phase
after stroke is pneumonia. It accounts for 15%-25% of
stroke deaths. Pneumonia may be caused by aspiration153
or may be hypostatic in origin due to poor coughing and
immobilization. To reduce the risk of aspiration pneumo-
nia in patients with reduced consciousness, or with im-
paired gag reflexes or with swallowing disturbances,
nasogastric feeding may be introduced. Hypostatic pneu-
monia may be prevented by frequent changes of the
patient’s position in bed and pulmonary physical therapy.
Urinary tract infection
Urinary tract infection may develop due to urinary
retention in the early stroke phase. Urinary incontinence
is a frequent stroke complication leading to the use of
indwelling catheters. Intermittent catheterization is not
always feasible in the setting of severe stroke and may
contribute to decubitus ulcer. Suprapubic catheters are
considered to carry a lower risk of infection. Acidification
may reduce the risk of infection. Once urinary infection
is seen, appropriate antibiotics should be started. How-
ever, there is no need for prophylactic antibiotics or treat-
ment of catheter colonization.
Pulmonary embolism (deep vein thrombosis)
Pulmonary embolism may be the cause of 5% of stroke
deaths. Early mobilization and use of subcutaneous hep-
arin or molecular weight heparin can reduce the risk of
deep venous thrombosis and pulmonary embolism. How-
ever, this effect seems to be counterbalanced by an increase
in hemorrhagic complications109. Nevertheless, prophy-
laxis with subcutaneous low-dose heparin (7 500-10 000
IU every 12 h) has been recommended for bedridden
stroke patients. Tachypnea and pain are sensitive signs of
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pulmonary embolism. Examination of the lower extremi-
ties should be performed daily to detect signs of deep vein
thrombosis. Physical therapy and support stockings are
suggested as an alternative.
Decubitus ulcers
Frequent turning of immobilized patients is useful for
prevention of decubitus. The skin of incontinent patients
must be kept dry. For patients at a particularly high risk,
an air- or fluid-filled mattress system should be used. If
the decubitus does not respond to conservative therapy,
antibiotic therapy may be justified for several days, pre-
ceding definitive surgical debridement.
Seizures
Partial or secondary generalized epileptic seizures may
occur in the acute stroke phase. Diazepam (10-20 mg iv)
followed by carbamazepine po is the treatment of choice.
Recommendations
1. Administration of heparin or low molecular weight
heparin is recommended in bedridden stroke patients
to reduce the number of deep vein thromboses and
pulmonary embolisms, however, there is a risk of ad-
ditional intracranial bleeding (Level I).
2. Infections after stroke should be treated with antibi-
otics and antipyretics. Aspiration pneumonia may be
prevented by nasogastric feeding.
3. Early mobilization is helpful to prevent numerous com-
plications after stroke: aspiration and hypostatic pneu-
monia, deep vein thrombosis and decubitus ulcers.
4. In seizure recurrence, administration of anticon-
vulsants is recommended (Level III).
5. Prophylactic administration of anticonvulsants to pa-
tients with recent stroke who have not had seizures is
not recommended.
PART IV NEUROREHABILITATION
Early stroke rehabilitation is a key consideration in
acute stroke management. A patient suffering from stroke
often has severe impairments and functional limitations
in action and perception. More than 40% of stroke survi-
vors remain dependent upon others for their activities of
daily living, about 25% are hospitalized, 10% are unable
to walk, and 66% cannot return to work156. Some studies
have suggested that early physical therapy helps in func-
tional improvement and reduces the number of patients
who are left dependent after stroke157. The principal aims
of stroke rehabilitation should be to prevent contractures
and embolism, optimize treatment associated with spe-
cific medical problems and provide psychological support
to patients and families.
Early rehabilitation
Almost half of all stroke patients need active rehabili-
tation services. Rehabilitation should be started as soon
as possible, even in comatose patients, who benefit from
proper positioning and range-of-motion exercise. This
means that the stroke patient should immediately be
brought to a hospital with such facilities not only because
of acute diagnosis and therapy but also because of early
rehabilitation. The intensity of the rehabilitation program
depends on the status of the patient and the degree of
disability. If the patient is unconscious, the rehabilitation
is passive to prevent contractions and joint pain, and to
prevent distress for the patient when movement is re-
started after immobilization. With passive rehabilitation,
one can also minimize the risk of decubitus ulcers and
pneumonia. All joints on the paralyzed side are moved
through the full range of motion several times a day (3-4
times at least). Patients rarely need to be immobilized in
bed for more than 1 or 2 days after a stroke unless they
have a major decrease in their level of consciousness. Pro-
longed immobilization and hemiplegia carry a risk of deep
vein thrombosis and complication of pulmonary embo-
lism. After 2 or 3 days, most patients who are alert can
be moved out of bed with safety and placed in either a
wheel-chair or fixed chair for a good part of the day.
Rehabilitation programs
Early and adequate prediction of functional recovery
after stroke is important in order to facilitate proper dis-
charge planning, anticipate the need for home adjust-
ments and community support, and set realistic and at-
tainable goals for treatment. Important predictors for
functional recovery after stroke are: disability on admis-
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sion, sitting balance, severity of paralysis, urinary incon-
tinence, level of consciousness within 18 hours post-
stroke, and age. The assessment of the patient’s situation
includes evaluation of intellectual impairment including
specific cognitive deficits such as aphasia, agnosia, apraxia,
mood motivation, and degree of motor weakness, sensory
loss and visual loss. Other problems that influence the
patient’s ability to respond to rehabilitation include finan-
cial burden, chances of return to activities and work, ability
to live at home, sexual function, and need of other people’s
help. Ideally, the multidisciplinary stroke team who pro-
vide for adequate rehabilitation for stroke victims, consists
of a stroke physician, nurses experienced in stroke man-
agement, a physiotherapist trained in stroke rehabilitation,
an occupational therapist skilled in stroke care, a speech
therapist familiar with speech problems in stroke, a neu-
ropsychologist accustomed to stroke rehabilitation, and a
social worker. Unfortunately, most hospitals treating
stroke patients do not have all of these specially trained
stroke experts. Still, it remains unclear which part of the
expert care is mostly ameliorating stroke prognosis.
Among the factors, involvement of active family partici-
pation, special staff education, early start of treatment or
intensity of treatment are most prominent. Several lines
of evidence suggest that intensity of treatment is a key as-
pect of stroke rehabilitation155,157.The progress of the pa-
tient needs to be followed on a daily basis, by different
members of the rehabilitation program. The patients and
members of their families should be taken to be members
of the stroke team. They should be taught the principles
of stroke rehabilitation, so that they can actively partici-
pate in it. As soon as the patient’s condition allows it, they
should visit their home, and if they need longer rehabili-
tation period, they should be transferred to a special re-
habilitation hospital. At the same time, the documenta-
tion of the patient and the progress in rehabilitation
should be transferred too.
The recovery of the neurologic deficit occurs fastest
during the first three months after the onset of symptoms.
This is also the optimal time for rehabilitation. Still, ac-
tive rehabilitation should be continued for as long as
needed as part of a long-term rehabilitation program.
Such a program includes twice a year a series of 15-20
physiotherapy sessions. This is to guarantee that the func-
tional status, which has been achieved during the acute
rehabilitation program, is sustained. If maintenance of the
recovery is in jeopardy, an active rehabilitation program
is needed, and sometimes it is reasonable to readmit the
patient for a more intensive inpatient rehabilitation pe-
riod.
Rehabilitation programs do not change the neurologic
deficit, but patients can become ambulatory and largely
independent. Of more importance is the fact that a ma-
jority of patients are able to be at home and do not require
nursing home care. A better outcome of stroke is of ben-
efit in both human and economic terms.
Recommendations
1. Rehabilitation should be initiated early after stroke
(Level I).
2. Every patient should have access to evaluation for re-
habilitation (Level III).
3. Rehabilitation services should be provided by a multi-
disciplinary team (Level III).
PART V SECONDARY PREVENTION
Secondary prevention means treatment and rehabilita-
tion of patients who have had a stroke or transient ischemic
attack, in order to prevent recurrent stroke. Secondary pre-
vention also means identification and treatment of persons
at a very high risk of developing stroke to prevent stroke
occurrence. Secondary prevention can extend overall sur-
vival, improve quality of life, decrease the need of surgical
procedures, and reduce the incidence of subsequent strokes.
Secondary prevention comprises changing of lifestyle: quit-
ting smoking, increasing physical activity, reducing body
weight, changing eating habits, etc., treatment of concomi-
tant diseases: hypertension, diabetes, elevated plasma lip-
ids, cardiac diseases, atrial fibrillation, etc.; prescribing drugs
for secondary prevention of ischemic stroke and surgical
interventions: carotid endarterectomy and angioplasty158.
Changing of lifestyle, treating of concomitant disease, and
surgical interventions are measures of secondary prevention
for ischemic as well as for hemorrhagic stroke, while pre-
scribing antiplatelet and anticoagulant drugs are reserved
only for secondary prevention of ischemic stroke.
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Changing of lifestyle and treatment of concomitant
diseases are described in Part I. Primary prevention. Ev-
erything that is said there could and must be applied in
secondary prevention.
DRUGS FOR SECONDARY
PREVENTION OF ISCHEMIC STROKE
ANTIPLATELET DRUGS
In the secondary prevention of ischemic stroke, anti-
platelet drugs are prescribed, most often acetylsalicylic
acid, ticlopidine, clopidogrel and dipyridamole.
Acetylsalicylic acid
Acetylsalicylic acid is a drug that has been in use for
more than 100 years, and it is the best studied medical
therapy for preventing stroke. The Antiplatelet Trialists’
Collaboration performed a meta-analysis of 145 trials in-
volving 51,144 patients allocated to antiplatelet therapy159.
They found a 25% (20%-28%) reduction in stroke risk
among patients receiving acetylsalicylic acid. The optimal
dose of acetylsalicylic acid has not yet been defined. Usu-
ally, the dose of acetylsalicylic acid is defined as low (<160
mg), medium (160-325 mg) and high (500-1500 mg) dose.
It has been debated that low doses could be more effective
than medium or high doses because the production of
prostacyclin by the endothelial cells may be partially pre-
served160. In European countries, acetylsalicylic acid is
mainly prescribed in low and medium doses161, while in the
United States acetylsalicylic acid is mainly prescribed in
high doses162. However, studies that compared the effects
of various doses of acetylsalicylic acid have failed to show
differences in stroke recurrence between low and medium
doses163 or between medium and high doses164. According
to the findings of the Antiplatelet Trialists’ Collabora-
tion159, the most widely tested were doses between 160 and
325 mg per day, and these doses may be most beneficial.
However, there also exists evidence that doses of 30 and 50
mg daily are effective163-165. It seems that acetylsalicylic acid
in any daily dose, 30 mg or higher, leads to moderate but
significant reduction of stroke. A major side effect of ace-
tylsalicylic acid therapy is bleeding. The rate of severe hem-
orrhages (those requiring blood transfusion or hospitaliza-
tion) is not dose-dependent. However, higher doses in-
crease the incidence of gastrointestinal side effects, e.g.,
indigestion, heartburn, nausea, vomiting. The recom-
mended dose of acetylsalicylic acid therefore should be
between 50 and 325 mg166.
Ticlopidine
Ticlopidine is a thienopyridine derivative that inhibits
the adenosine diphosphate pathway of platelet aggregation.
In the Canadian American Ticlopidine Study (CATS),
ticlopidine (500 mg/day) showed a risk reduction for stroke
by 33.5% compared to placebo167. In the Ticlopidine As-
pirin Stroke Study (TASS), ticlopidine (500 mg/day) in in-
tention-to-treat analysis showed a reduction of 21% com-
pared with acetylsalicylic acid (1300 mg/day) for fatal and
nonfatal stroke168. Ticlopidine, therefore, compares better
to acetylsalicylic acid in the secondary prevention of is-
chemic stroke. A major disadvantage of ticlopidine are gas-
trointestinal side effects: diarrhea, dyspepsia and bleeding,
skin rashes and bone marrow side effects: neutropenia,
thrombocytopenia, and thrombotic thrombocytopenic pur-
pura. Most of these side effects occur in the first three
months, but thrombotic thrombocytopenic purpura can
occur even after the first three months169,170. Ticlopidine
is a drug with more side effects than acetylsalicylic acid, and
it is also more expensive.
Clopidogrel*
Clopidogrel is a new thienopyridine derivative, chemi-
cally related to ticlopidine. The Clopidogrel versus Aspi-
rin in Patients at Risk of Ischemic Events (CAPRIE)
study compared the effects of 75 mg clopidogrel and 325
mg acetylsalicylic acid once daily in reducing the compos-
ite endpoint of ischemic stroke, MI, or vascular death in
19,185 patients, and found a significant 8.7 % relative
reduction in events in favor of clopidogrel171. Clopidogrel
is slightly but significantly more effective than medium-
dose acetylsalicylic acid. The side effects of clopidogrel
and acetylsalicylic acid were similar. Recently, an article
was published on 11 cases of thrombotic thrombocy-
topenic purpura associated with clopidogrel use172.
Clopidogrel is the agent of choice in patients with
contraindications or adverse effects to acetylsalicylic acid,
and may be more effective in higher risk patients173. How-
ever, clopidogrel is more expensive than acetylsalicylic
acid.* Drug not registered in Croatia
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Dipyridamole*
Dipyridamole is an antiplatelet agent with inhibition
of cyclic nucleotide phosphodiesterase and blockage of the
uptake of adenosine174. Four trials investigated whether
the combination of dipyridamole plus acetylsalicylic acid
is superior to acetylsalicylic acid alone and all had nega-
tive findings175-178. The European Stroke Prevention
Study II165 analyzed 6602 patients with stroke or TIA
who were randomized to acetylsalicylic acid alone (50 mg
daily), extended-release dipyridamole alone (400 mg
daily), acetylsalicylic acid plus extended-release dipy-
ridamole (50 + 400 mg daily), or placebo. The risk reduc-
tion in stroke events in the acetylsalicylic acid plus dipy-
ridamole group (37%) was significantly higher than in
either the acetylsalicylic acid group (18.1%) or dipy-
ridamole group (16.3%). Although this study was viewed
with some criticism, the results of the statistically adequa-
tely powered study clearly demonstrate the superiority of
the combined treatment: acetylsalicylic acid (25 mg) plus
extended-release dipyridamole (200 mg) twice daily.
Recommendations
1. Low- or medium-dose acetylsalicylic acid (50-325
mg) should be given as first-choice agent to reduce re-
currence of ischemic stroke (Level I). Alternatively,
where available, a combination of acetylsalicylic acid
(25 mg) and dipyridamole (200 mg) twice daily may
be given as first choice therapy (Level I).
2. Ticlopidine is in some aspects superior to acetylsali-
cylic acid in secondary prevention of ischemic stroke
(Level I). Owing to the side effects of ticlopidine, it
should be prescribed only to patients who cannot take
acetylsalicylic acid (Level I).
3. Clopidogrel is slightly more effective than acetylsali-
cylic acid (Level I). It may be prescribed as first choice
therapy or when acetylsalicylic acid is not tolerated or
effective, and in special situations such as high-risk
patients (Level III).
4. Patients starting treatment with thienopyridine de-
rivatives should receive clopidogrel instead of ticlo-
pidine because it has fewer side effects (Level I). Pa-
tients who have already been receiving ticlopidine for
a long time should be maintained on this regimen be-
cause the most severe side effects (neutropenia and
rash) occur at the beginning of treatment.
5. Patients who do not tolerate acetylsalicylic acid, ticlo-
pidine or clopidogrel may be treated with dipyrida-
mole (ret., 2x200 mg daily; Level I).
Anticoagulants after cardioembolic ischemic stroke
Oral anticoagulation with maintaining of Interna-
tional Normalized Ratio (INR) between 2.0-3.0 reduces
the risk of recurrent stroke in patients with atrial fibrilla-
tion and recent ischemic stroke163. Oral anticoagulation
therapy should also be considered for the many well es-
tablished potential causes of embolism. Although evi-
dence from randomized trials is still lacking, long-term
anticoagulants are routinely used in patients with mecha-
nical prosthetic valves. In this setting, a higher target of
an INR of between 3.0 and 4.0 is recommended179. Long-
term anticoagulation with an INR of 2-3 in patients with
rheumatic valvular heart disease, MI, heart failure, cardi-
omyopathy, arrhythmia other than AF, or patent foramen
ovale may be indicated.
Recommendations
1. Oral anticoagulation (INR 2.0-3.0) is indicated after
ischemic stroke associated with atrial fibrillation
(Level I).
2. Patients with mechanical prosthetic valves should re-
ceive long-term anticoagulation therapy with a target
INR between 3.0 and 4.0 (Level III).
3. Patients with confirmed cardioembolic stroke should
receive anticoagulation if the risk of recurrence is high,
with a target INR between 2.0 and 3.0 (Level III).
SURGERY
Carotid endarterectomy
The North American Symptomatic Carotid Endart-
erectomy Trial Collaboration (NASCET)59 and European
Carotid Surgery Trial (ECST)60 found carotid endarter-
ectomy to be effective in symptomatic patients with ipsi-
lateral carotid stenosis greater than 70%. Although these
trials used different methods to measure stenosis, it is po-
ssible to predict the percentage of stenosis from one me-* Drug not registered in Croatia
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thod to another, and there is little difference in their ability
to predict ipsilateral stroke.
In the NASCET, patients who underwent carotid en-
darterectomy had an absolute reduction of 17% in the risk
of ipsilateral stroke at 2 years. The authors therefore warn
that the benefit of surgical procedure diminishes when
perioperative complications exceed 2.1%, and that it van-
ishes entirely when the rate approaches 10%. Although
the rate of perioperative complications in the ECST was
higher (7.5% of deaths, disabling stroke, or any stroke
producing symptoms for more than 7 days), surgery-allo-
cated patients still had a significant absolute risk reduc-
tion of 6.5 % in ipsilateral stroke and a relative reduction
of 39%. The recent NASCET analysis of surgery for
symptomatic patients with less than 70% stenosis revealed
an absolute risk reduction of 6.5% and a relative risk re-
duction of 29% in patients with 50%-69% stenosis allo-
cated for surgery180.
Angioplasty and stenting
Carotid percutaneous transluminal angioplasty is a
potentially valuable technique. Its advantages over carotid
endarterectomy are short hospital stays, avoidance of gen-
eral anesthesia and surgical incision, and ability to treat
surgically inaccessible sites such as internal carotid artery
stenosis at the base of the skull. Moreover, carotid percu-
taneous transluminal angioplasty and stenting may be the
most effective means of treating restenosis after initial
carotid endarterectomy 182. Since this procedure has only
recently been used, the principal problem is that data on
long-term follow-up and comparison with carotid endar-
terectomy are not yet available. Randomized trials are
planned. In the meantime, carotid percutaneous translu-
minal angioplasty may be considered as an experimental
alternative to carotid endarterectomy. The results of the
Carotid and Vertebral Artery Transluminal Angioplasty
Study, the first randomized comparison of angioplasty and
carotid endarterectomy, were presented at several confer-
ences but have not yet been published.
Recommendations
1. Carotid endarterectomy is indicated for symptomatic
patients with stenosis of 70%-99%, but only in cen-
ters with a perioperative complication rate (all strokes
and death) less than 6% (Level I).
2. Carotid endarterectomy may be indicated for some
patients with stenosis of 50%-69% without a severe
neurologic deficit. This is also valid only for centers
with a perioperative complication rate (all strokes and
death) less than 6%. The subgroup of patients most
likely to benefit from surgery are males with recent
hemispheric symptoms (Level I).
3. Carotid endarterectomy is not recommended in pa-
tients with stenosis less than 50% (Level I).
4. Carotid endarterectomy should not be performed in
centers not exhibiting low complication rates equal to
those in NASCET and ECST.
5. Carotid endarterectomy may be indicated for some
patients with stenosis of 60%-99%. Only patients with
a low surgical risk (<3%) and with a life expectancy of
at least 5 years are likely to benefit from surgery (Level
II)
6. Carotid PTA with or without stenting may be per-
formed in patients with contraindications for carotid
endarterectomy (Level IV).
7. Carotid percutaneous transluminal angioplasty with or
without stenting may be indicated in patients with
stenosis at surgically inaccessible sites (Level IV).
8. Carotid percutaneous transluminal angioplasty and
stenting may be indicated in patients with restenosis
after initial carotid endarterectomy (Level IV).
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